CVS Health Corporation (CVS): Jim Cramer Says You Don't Want Them Buying The Wrong Robots
CVS Health Corporation (NYSE:CVS) is one of the largest pharmaceutical retailers in America. The firm's shares have gained 44% year-to-date due to weakness at the firm's primary rival Walgreens. Cramer's previous remarks about CVS Health Corporation (NYSE:CVS) have praised the firm's CEO and his turnaround efforts. The shares gained 4% in May after the firm raised its 2025 profit forecast to a midpoint of $6.10 per share from an earlier $5.87 per share. CVS Health Corporation (NYSE:CVS)'s turnaround efforts which have seen the firm appoint a new CEO and exit its Obamacare direct sales business have contributed to the strong 2025 share price performance. In his recent comments about CVS Health Corporation (NYSE:CVS), Cramer wondered what would happen if the firm automated its pharmacies through robots:
'I mean one of the things that is really meant to be changing here is healthcare. And you don't want, uh, CVS, for instance, if they were to buy a robot, you don't want them saying, do remember that scene, It's a Wonderful Life, where the pharmacist gave them the wrong prescription? You don't want that. You don't want It's a Wonderful Life, to be your life.'
In his previous comments, the CNBC host praised the firm's management. Here's what he said:
'Now we've got some healthcare, some issues to talk about on Thursday, that's right, and these are anything but common steady healthcare companies…. There's CVS, which is under new management, put up some really good numbers, and it's just, that's in health insurance, but also it's core drugstore business, which they've closed, all the under performers… As for CVS, the health insurers have taken it on the chin of late. UnitedHealth and Centene both missed expectations. I bet Aetna sticks it.'
A row of shelves in a retail pharmacy, demonstrating the variety of drugs and over-the-counter products.
Overall, CVS ranks 11th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of CVS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: and .
Disclosure: None. This article is originally published at .
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
25 minutes ago
- Business Wire
PPG Board of Directors approves dividend increase to 71 cents per share
PITTSBURGH--(BUSINESS WIRE)--The Board of Directors of PPG (NYSE:PPG) today approved a 3-cents-per-share increase in the company's dividend, declaring a regular quarterly dividend of 71 cents per share, payable Sept. 12 to shareholders of record Aug 11. This marks the company's 508th consecutive dividend payment. Through the ongoing dedication and engagement of its workforce, the company has paid uninterrupted annual dividends since 1899. 'We are proud of PPG's long heritage of rewarding shareholders and are pleased to increase our dividend per share,' said Tim Knavish, PPG chairman and chief executive officer. 'This dividend growth reflects the strong confidence that PPG's Board has in the resiliency of our business and the strength and future growth of our company.' PPG: WE PROTECT AND BEAUTIFY THE WORLD® At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and specialty materials that our customers have trusted for more than 140 years. Through dedication and creativity, we solve our customers' biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 70 countries and reported net sales of $15.8 billion in 2024. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit The PPG Logo and We protect and beautify the world are registered trademarks of PPG Industries Ohio, Inc. CATEGORY Financial
Business Wire
25 minutes ago
- Business Wire
Ategrity Specialty Insurance Company Holdings to Announce Second Quarter 2025 Earnings on August 11, 2025
NEW YORK--(BUSINESS WIRE)--Ategrity Specialty Insurance Company Holdings (NYSE: ASIC) (the 'Company') announced today that it will release financial results for the second quarter ended June 30, 2025, after the market closes on Monday, August 11, 2025. These documents will be available on the Company's Investor Relations website at The Company will host a conference call to discuss its results on the same day, Monday, August 11, 2025, beginning at 5:00 p.m. Eastern Time. Interested parties may access the conference call via a live webcast, which can be accessed at or by visiting the Company's Investor Relations website. Please join the webcast at least 10 minutes before the scheduled start time. A replay of the event webcast will be available on the Company's Investor Relations website approximately two hours following the call, for a period of at least 30 days. About Ategrity Specialty Insurance Company Holdings Ategrity Specialty Insurance Company Holdings is a growing specialty insurance company dedicated to providing excess and surplus ('E&S') products to small to medium-sized businesses across the United States. We have built a proprietary underwriting platform that combines sophisticated data analytics with automated and streamlined processes to efficiently serve our clients and deliver long-term value to our stockholders. The small to medium-sized business market is characterized by large volumes of small-sized policies, and we believe our competitive edge lies in our ability to offer consistent, high-speed, and low-touch interactions that our distribution partners value. This advantage stems from our technology-driven method of standardizing, simplifying, and automating our transaction process, which we call productionized underwriting.
Yahoo
44 minutes ago
- Yahoo
Johnson & Johnson's Healthy 3.3%-Yielding Dividend Is a Very Safe Way to Make Passive Income
Key Points Johnson & Johnson continues to generate plenty of free cash flow to cover its dividend. The healthcare giant also maintains an elite balance sheet. With more growth ahead, it should have no trouble continuing to increase its high-yielding payout. 10 stocks we like better than Johnson & Johnson › Johnson & Johnson (NYSE: JNJ) has been an extremely reliable dividend stock for decades. The healthcare behemoth has raised its payment for 63 straight years, including by 4.8% earlier this year. That places it in the elite group of Dividend Kings -- companies with 50 or more consecutive years of increasing their dividend payouts. The healthcare company's payout currently yields 3.3%, more than double the S&P 500's (SNPINDEX: ^GSPC) dividend yield (near a record low at around 1.2%). That high-yielding payout is very healthy, making Johnson & Johnson a very safe way to collect dividend income. A financial fortress Johnson & Johnson recently reported its second-quarter financial results, which once again showcased the safety of its dividend payment. The healthcare company reported that it generated approximately $6.2 billion in free cash flow through the first half of this year, following investments of $6.7 billion in research and development (R&D). That was enough cash to cover its dividend payment, which has cost $6.1 billion year to date. While that might seem like a tight payout ratio, investors need not be concerned. Its free cash flow is only down slightly compared to the year-ago period, when it produced $7.5 billion through the first half of the year. Johnson & Johnson generated $20 billion in total free cash flow last year, easily covering its $11.8 billion dividend outlay. Meanwhile, Johnson & Johnson has one of the best balance sheets in the world. The company has a pristine AAA bond rating (one of only two companies in the world with elite credit). It ended the first quarter with $19 billion of cash and marketable securities on its balance sheet (nearly two years of dividend payments) against only $51 billion of debt. The $32 billion in net debt is a relatively small amount for a company with a roughly $375 billion market capitalization. Johnson & Johnson has maintained a strong balance sheet, even as it has deployed $15 billion in strategic inorganic growth opportunities over the past year, and more than $30 billion over the last two years. Investing heavily to grow Johnson & Johnson's robust financial profile enables it to invest heavily in R&D and M&A, driving growth of its innovative medicine and MedTech platforms. Last year, the company spent more than $17 billion in R&D (19.4% of its total sales). That made it one of the top R&D investors across all industries. Adding acquisitions and other inorganic investments, the company invested a whopping $50 billion in growth initiatives last year. Those growth investments are starting to pay off. "Our portfolio and pipeline position us for elevated growth in the second half of the year," commented CEO Joaquin Duato in the second-quarter earnings press release. As a result, the company boosted its annual revenue guidance by $2 billion (implying 5.4% growth for the full year) and tacked $0.25 per share to its adjusted earnings per share outlook, increasing the midpoint to $10.68. The company anticipates it will continue growing at a healthy pace over the next few years. By 2027, Johnson & Johnson expects that one-third of its MedTech sales will come from new products. Meanwhile, the company expects to launch more than 10 innovative medicine assets by 2030, with the potential to deliver over $5 billion in peak-year sales. The growth from these products will help to more than replace the lost sales from expiring patents, enabling the company to continue increasing revenue and free cash flow at healthy rates. It can also continue utilizing its fortress balance sheet to supplement its R&D efforts with strategic M&A opportunities as they arise. A very safe dividend stock Johnson & Johnson continues to showcase its elite ability to pay dividends. The healthcare company's high-yielding payout remains on rock-solid ground, even though its free cash flow is down through the first half of this year. With a fortress balance sheet and visible growth ahead, the company should have no problem continuing to increase its dividend at a healthy pace. As a result, it remains an extremely safe way to generate passive dividend income. Do the experts think Johnson & Johnson is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Johnson & Johnson make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,060% vs. just 179% for the S&P — that is beating the market by 881.02%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $679,653!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,046,308!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Matt DiLallo has positions in Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy. Johnson & Johnson's Healthy 3.3%-Yielding Dividend Is a Very Safe Way to Make Passive Income was originally published by The Motley Fool
